Record year for pharma deals but firms fail to sell mature-drug portfolios
London
IN A record year for healthcare acquisitions, some of the largest pharmaceutical companies tried to sell their portfolios of older drugs - and failed.
Drug companies have agreed to about US$260 billion of deals so far in 2014, the most since at least 2002 and more than twice the volume last year, according to data compiled by Bloomberg. Fuelled by cheap debt, buyers like Actavis and Merck paid substantial premiums amid competition for new drug pipelines.
Meanwhile, sales of mature-drug portfolios - made up of older medicines such as Sanofi's blood thinner Plavix and GlaxoSmithKline's anti-…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Stocks to watch: MPACT, CapitaLand Ascott Trust, Hotel Properties, OUE Reit, CCT
CapitaLand China Trust posts 7.7% drop in Q1 NPI to 313.1 million yuan
Apparel company Express seeks quick bankruptcy sale
First Reit reports 3.2% lower Q1 DPU of S$0.006 amid interest rate, forex headwinds
Tesla profits tumble but shares rise on new vehicle plan
Hong Kong crypto ETF launches will test ambition to be digital-asset hub